

Original Research Article

Cardiovascular Evaluation Before and After Splenectomy In β Thalassemia in Children

ABSTRACT

Background: Cardiac complications represent the leading cause of mortality and morbidity in β thalassemia, with iron overload and high output state being the main precipitating factors. Splenectomy, on the other hand, is an established therapeutic intervention in β thalassemia which is decided upon certain indications but the effects of splenectomy on cardiovascular function in β thalassemia have not been established yet and there is very few study in this regard in other country. **Objective of the study:** To evaluate the effect of splenectomy on cardiovascular function in β thalassemia. **Methodology:** This longitudinal type of descriptive observational study was done in the department of Paediatric Surgery, MMCH from January 2017 to April 2018 among the 20 β thalassemia patients with indication of splenectomy who fulfill the inclusion criteria. All patients were evaluated by detailed history, clinical examination and reviewing past medical reports. Informed consent was taken from all patients or their parents and then all patients were advised for relevant investigations. After preparing the patients splenectomy was done under general anesthesia. After splenectomy all patients were followed up for 6 months. All patients were evaluated in regards of haematological profile and echocardiographic parameters 6 months prior to and 6 months following splenectomy and all findings of before splenectomy were compare to those 6 months following splenectomy. Data was analyzed by statistical package for social sciences (SPSS) version 20. **Results:** The mean age was of the patients at splenectomy was 8.18 ± 2.59 years. Among the 20 cases 12 (60.00%) were male and 8 (40.00%) were female with the ratio 1.5:1, male predominant. All patients were transfusion dependent thalassemia among them maximum 16 (80%) was severe Hb E/ β thalassemia and 4 (20%) was β thalassemia major. Major indication of splenectomy 14(70%) was increased requirement of blood transfusion. Mean 6-monthly pretransfusion hemoglobin was significantly increased after splenectomy from 4.19 ± 0.92 to 8.66 ± 0.73 g/dl ($p < 0.001$). Postoperatively, the 6-monthly transfusion requirements were significantly reduced from 14.30 ± 3.18 to 2.15 ± 1.46 units ($p < 0.001$), while blood transfusions were discontinued in 4 patients (20%). The mean serum ferritin was not significantly different after surgery ($p > 0.05$). All 20 patients were in a high output state, with mean cardiac output being 5.85 ± 1.72 L/min in patients versus 3.6 ± 1.03 L/min in controls ($p < 0.001$). Postoperatively, cardiac output was significantly reduced from 5.85 ± 1.72 L/min to 4.99 ± 1.64 L/min ($p < 0.05$). Other parameters were not significantly different after surgery ($p > 0.05$). Before splenectomy 3(15%) patient clinically developed Heart failure and after splenectomy out of 3 heart failure patients 1(5%) have features of restrictive cardiomyopathy in echocardiogram and 2(10%) have normal findings except high cardiac output. **Conclusion:** Splenectomy stabilizes the hemoglobin concentration at higher levels and reduces transfusion needs, reduces high cardiac output and prevent high output failure. Though other cardiac parameters remain unchanged within the first 6 months after splenectomy, it can be assumed that removal of the spleen may contribute to the prevention of further cardiac damage.

Key words: β thalassemia, Splenectomy, cardiovascular, Paediatric.

INTRODUCTION

Thalassemia is the most common hereditary disorder in the world including Bangladesh [1]. According to WHO reports, approximately 3% of populations are carriers of β thalassemia and 4% are carriers of HbE/ β thalassemia in Bangladesh [2]. The basic defect in β thalassaemia is a reduced or absent production of β globin chains with relative excess of α -chains [3]. Excess free α chains aggregate into insoluble inclusions within red cells and their precursors, leading to premature destruction of erythroblasts in the marrow (ineffective erythropoiesis) & lysis of mature red cells in the spleen (hemolysis) [4]. To compensate for the reduced hemoglobin, the synthesis of gamma chains persists after fetal life even beyond 6 months of age. The normal switch mechanism leading to reduction in γ -chain synthesis does not occur and leads to higher fetal hemoglobin $\alpha_2\gamma_2$ (HbF) in postnatal life [5]. Prognosis for individuals with β thalassemia has improved substantially in the last 20 years following recent medical advances in transfusion, iron chelation and bone marrow transplantation therapy. However, cardiac disease remains the main cause of death in patients with iron overload [6]. Enlargement of spleen is due to both extra medullary haematopoiesis and entrapment of abnormal shape RBC's, excessive destruction of abnormal RBCs & transfusional overload. Splenomegaly further increases transfusional requirement. So, these patients benefit from splenectomy. Splenectomy is indicated when blood transfusion exceed 250ml/kg/year,

hypersplenism, abdominal discomfort due to massive splenomegaly and splenic injury [7]. Various studies showed benefits of splenectomy in β thalassemia. [8] reported splenectomy improved the quality of life in form of school going, sports and decreased in abdominal discomfort. Patient's health improved after splenectomy because of improvement in haemoglobin level and decrease in blood transfusion requirement. Effect of splenectomy on iron balance is controversial [9] in his study concluded that Splenectomy improves anemia, but does not reduce iron burden.

All guidelines agree that physicians should adopt a guarded approach and restrict splenectomy to certain indications, in view of the observation of an increased risk of venous thrombosis and pulmonary hypertension, alongside overwhelming infections after splenectomy. Splenomegaly due to periods of under-transfusion with blood of inappropriately low haemoglobin may be reversible [10]. Over the course of the past 2-3 decades, hyper transfusion therapy has significantly increased the life expectancy and improved the quality of life of these patients. At the same time, there has been an increase in the frequency of complications of this therapy caused by iron overload [11]. The iron deposits in thalasseemics, who have received multiple blood transfusions, can exceed the storage and detoxification capacity of ferritin. Consequently, "free" iron begins to accumulate in tissues and blood [12]. Most of the complications of β thalassemia are attributable to iron overload. Complications of iron overload in children include growth retardation and failure or delay of sexual maturation. Later iron overload related complications include involvement of the heart, liver and endocrine glands [13]. Heart complications remain the major cause of mortality in β thalassemia major. The combination of iron mediated toxicity with increased cardiac output is associated with development of heart failure [14]. In heart, the iron leads to impaired function of the mitochondrial respiratory chain, which is clinically manifested by the reduction of cardiac contractility, progressive systolic dysfunction, and development of heart failure [15]. Chronic anemia is responsible for an increase in cardiac output, results from decreased systemic vascular resistance due to decreased blood viscosity and vasodilatation [16]. In several studies, diastolic ventricular dysfunction demonstrated in these patients preceded the onset of systolic impairment [17]. Regular assessment of cardiac function may help to improve the quality of life of these patients and may reduce the morbidity and mortality to a great extent Echocardiography is a non-invasive technique that evaluates cardiac anatomy and function with images and recordings produced by sound energy [13]. Even after significant toxic effects on heart muscle have prevailed, aggressive iron chelation can restore myocardial function to normality [18]. Therefore, regular assessment of iron status is essential for the efficient management of iron overload in β thalassemia patients. Serum ferritin is simple, inexpensive and available method for evaluating iron in thalassemia patients and ferritin is generally associated with the amount of stored iron in the body [19]. This study was conducted in the Department of Paediatric Surgery, Mymensingh Medical College and Hospital from January, 2017 to April, 2018 to evaluate cardiovascular function before and after splenectomy in β thalassemic patient in terms of haematological profile and echocardiographic evaluation of left ventricular function.

The aim of this study was to detect effect of splenectomy on cardiovascular function. This study will certainly serve baseline information for clinicians and other research workers about cardiovascular changes in β thalassemia due to iron overload and increased cardiac output before and after splenectomy, all of which can be easily follow up by echocardiogram and serum ferritin level. As echocardiography is easily available and can detect early cardiac involvement and it be can reverse with adequate iron chelation therapy, after splenectomy the thalassemic patient can be managed properly by regular follow up of iron status by serum ferritin and cardiac status by echocardiogram which will improve life expectancy of these patients.

MATERIALS AND METHODS

This study was Longitudinal type of descriptive observational study. Purposive type of non-probability sampling technique was followed for selection of cases. A total number of 20 patients, admitted in department of Paediatric Surgery in Mymensingh Medical College & Hospital, through the outpatient department who fulfill the inclusion criteria were selected in this study. Type of β thalassemia was recorded from past Hb electrophoresis report, if any patient have missing the report, repeat Hb electrophoresis was done to confirm the diagnosis. Indication of splenectomy was determined by evaluating transfusion requirement, splenomegaly and history of mechanical discomfort, past reports of Peripheral blood film and bone marrow examination was reviewed in patient who was diagnosed by a hematologist as suggestive of hypersplenism. All patients were vaccinated against capsulated organisms and after 14 days of vaccination admitted in department of

Paediatric surgery, Mymensingh Medical College Hospital (MMCH). After admission all patients were evaluated thoroughly & do all the relevant investigations including echocardiogram. Simultaneously patients were prepared for splenectomy. Blood transfusion was given to maintain Hb% 8-10gm/dl prior splenectomy for each patient. Among 20 patients, 3 patient was present with heart failure who were managed by correction of anaemia very cautiously with packed red cell and diuretics, frusemide 1-2mg/kg intravenous 12 hourly for 2-3days and then oral frusemide 2-3mg/kg in 2 divided dose for 3-4 days with monitoring of urine output and serum electrolytes. Among the 3 heart failure patients 1 had serum ferritin level >3000ng/dl, intravenous iron chelation for 5days was given in that patient according to guidelines for management of heart failure in β thalassemia patients. After proper counseling of parents and completion of all preoperative preparations, splenectomy was done under general anesthesia. Operative findings and post operative events were documented. Per operative and post operative periods were uneventful. Patients were discharged at 7th or 8th post operative period with advice of post splenectomy antibiotic prophylaxis and follow up schedule. Then patients were followed up at first 15 days after splenectomy and then 1 month interval up to 6 months. During each follow up patients general condition was evaluated and Hb% was done. Serum ferritin & Echocardiogram were done after 6 months of splenectomy. This study was conducted at the Department of Paediatric Surgery, Mymensingh Medical College, Mymensingh, Bangladesh. At January 2017 - April, 2018.

OBJECTIVES

General objectives

- To evaluate the effect of splenectomy on cardiovascular function in β thalassemia.

Specific objectives

- To determine the average age of splenectomy indication in β thalassemia.
- To detect blood transfusion requirement and mean pretransfusion hemoglobin level before & after splenectomy in β thalassemia.
- To detect effects of splenectomy on serum ferritin level.
- To determine the effects of chronic anemia and transfusion iron overload on left ventricular dimensions, systolic & diastolic function and cardiac output.
- To determine the effects of splenectomy on the left ventricular dimensions, systolic & diastolic function and cardiac output.

Inclusion criteria

- β thalassemia with huge splenomegaly causing mechanical discomfort.
- β thalassemia with blood transfusion requirement more than 250 ml/kg/year of packed red cells or more than 400 ml/kg/year of whole blood.
- β thalassemia with hypersplenism.
- Age range: 5-12 years.

Exclusion criteria

- Age <5 year
- β thalassemia with known congenital heart disease & other comorbidities.
-

Procedure of Data Collection:

In each case after obtaining written consent of the parents/ guardians in the consent form (Appendix-I) information from history, clinical examination was recorded in predesigned data collection sheet. After that all information

were gathered systematically and put into the same data collection sheet including all investigation findings, management & follow up findings (Appendix-II).

Statistical analysis:

Statistical analysis was performed with statistical package for social sciences (SPSS) version 20.0. Comparisons were performed by chi-square test for categorical variables, paired student’s t-test for quantitative variables. P value less than 0.05 were considered statistically significant.

Ethical Consideration:

The Ethical Review Committee (ERC) of Mymensingh medical college approved the protocol prior to commencement of the study in November, 2016. After starting of Institutional Review Board in Mymensingh Medical College, the IRB again approved the protocol and give certificate in 13th January, 2018.

RESULTS

This longitudinal type of descriptive observational study was carried out in the Department of Paediatric Surgery, Mymensingh Medical College Hospital during the period of January 2017 to April 2018. Total 20 patients were included in this study among them 12 were male and 8 were female with the ratio of male: female 1.5:1. The age ranges from 5 year to 12 years with the mean age of 8.18±2.59 years. All patients were selected purposively with β thalassemia having indication of splenectomy. All patients were evaluated by hematological profile and echocardiogram parameter. Echocardiographic data were compared before and after splenectomy and preoperative data were compared with control group from other study. The following observations were noted.

Table I. Age distribution No of patient (N = 20)

Age (in years)	No. of patients	Percentage
5-6	6	30.0
7-8	6	30.0
9-10	3	15.0
11-12	5	25.0
Total	20	100.00
Mean ± SD		8.18±2.59

Table I. Shows maximum patient 6 (30.00%) in age group (5-6) years and 6 (30.00%) in age group (7-6) years. The mean age was 8.18±2.59 years.

Table II: Sex distribution No of patient (n = 20)

Age in years	Sex			
	Male		Female	
	No	%	No	%
5-6	3	15	3	15
7-8	4	20	2	10
9-10	2	10	1	5

11-12	3	15	2	10
Total	12	60.00	8	40.00

Chi-square test, P=0.937 NS
d.f. 3, $\chi^2 = 0.417$
NS = Not significant, $p > 0.05$

Table II. Shows among the 20 cases 12 (60.00%) were male and 8 (40.00%) were female. Sex ratio of Male: Female = 1.5: 1 ($p > 0.05$).




Figure 1: Column Chart Showed Distribution of Patients According to Age Group and Sex

Table III. Patient's Hematological profile before and after splenectomy No of patients (n = 20)

	Before splenectomy	After splenectomy	t-value	P value
Mean 6-monthly Pre-transfusion hemoglobin (g/dl) ^a	4.19±0.92	8.66±0.73	23.038	0.000**
6-monthly transfusion requirement (units)	14.30±3.18	2.15±1.46	19.978	0.000**
Serum ferritin (ng/ml)	1346.25±616.40	1722.60±858.96	1.815	0.085 ^{NS}

^a Mean values of the last 6 months prior to and the first 6 months after splenectomy
Paired Student's 't' test

** P< 0.001(Highly significant); NS (Not significant)

Table III. Shows postoperatively mean 6-monthly pretransfusion hemoglobin level was significantly increased to 8.66 ± 0.73 g/dl from 4.19 ± 0.92 ($p<0.001$). 6-monthly transfusion requirements were significantly reduced postoperatively from 14.30 ± 3.18 to 2.15 ± 1.46 units ($p<0.001$) and mean serum ferritin levels were not significantly different after surgery ($p>0.05$).

Table IV. Echocardiographic parameters- Preoperative Left ventricular diameters and mass and cardiac output compared with control from other study No of patients (n=20)

	Controls (from other study)	Before splenectomy	t-value	P value
IVSTd (mm)	6.44±1.02	7.82±2.32	2.630	0.012*
IVSTs (mm)	9.84±1.32	11.00±2.13	2.400	0.021*
LVIDd (mm)	33.8±7.4	43.82±8.08	5.523	0.001**
LVIDs (mm)	17.8±5.8	26.23±5.45	6.875	0.000**
LVPWTd (mm)	3.99±0.49	7.84±2.07	8.213	0.000**
LVPWTs (mm)	4.13±0.48	11.61±2.69	12.339	0.000**
LV MASSd (gm)	57.2±12.3	100.30±51.21	3.763	0.001**
CO (L/min)	3.6±1.03	5.85±1.72	5.727	0.000**

Paired Student's 't' test

** P< 0.001(highly significant)

Table IV Shows All 20 patients were in a high output state, with mean cardiac output being 5.85 ± 1.72 L/min in patients versus 3.6 ± 1.03 L/min in controls ($p<0.001$). Other parameters were also significantly higher in patients compared to healthy ($p<0.01$).

Table V. Echocardiographic parameters - Left ventricular diameters and mass and cardiac output before and after splenectomy No of patients (n=20)

	Before splenectomy	After splenectomy	t-value	P value
IVSTd (mm)	7.82±2.32	11.00±13.78	1.013	0.324 ^{NS}
IVSTs (mm)	11.00±2.13	11.09±1.81	0.141	0.89 ^{NS}

LVIDd (mm)	43.82±8.08	43.14±6.45	0.995	0.332 ^{NS}
LVIDs (mm)	26.23±5.45	24.61±5.90	2.016	0.058 ^{NS}
LVPWTd (mm)	7.84±2.07	7.50±1.78	0.685	0.502 ^{NS}
LVPWTs (mm)	11.61±2.69	10.84±1.58	0.984	0.337 ^{NS}
LV MASSd (gm)	100.30±51.21	89.25±26.44	1.320	0.203 ^{NS}
CO (L/min)	5.85±1.72	4.99±1.64	2.529	0.020*

Paired Student's 't' test

** P< 0.001(highly significant); NS (Not significant)


Table V Shows cardiac output (5.85±1.72 L/min vs 4.99±1.64 L/min) was significantly reduced after splenectomy (p<0.05) and other parameters were not significantly different after splenectomy (p>0.05).

Table VI. Echocardiographic parameters - for systolic dysfunction (EF), diastolic dysfunction (E/A ratio) & pulmonary hypertension (PASP) No of patients (n=20)

	Normal values	Before splenectomy	After splenectomy	t-value	P value
EF (%)	>55	68.65±7.71	67.93±6.89	0.553	0.586 ^{NS}
E/A ratio	1-2	1.59±0.35	1.63±0.39	1.215	0.239 ^{NS}
PASP (mm of Hg)	≤36	28.40±9.13	29.15±9.30	1.958	0.065 ^{NS}

Paired Student's 't' test NS (Not significant)


Table VI Shows Mean EF (%), E/A ratio, PASP (mm of Hg) were within normal values and difference between before and after splenectomy was not significant (p>0.05).



3(15%) Patient clinically developed HF

Restrictive cardiomyopathy was encountered in 3 (15%), remain asymptomatic



Figure 1 I: Distribution of cardiac impairment before and after splenectomy (N=20)



Case-4: Echocardiogram before splenectomy (Stroke volume 92.1ml/min)

Case-4: Echocardiogram after splenectomy (Stroke volume 47.4 ml/min)


Photograph 01: Shows Echocardiogram before and after splenectomy of Case-4



Case-10: Echocardiogram before splenectomy (Stroke volume 87.7ml/min)

Case-10: Echocardiogram after splenectomy (Stroke volume 55.0 ml/min)

Photograph 02: Shows Echocardiogram before and after splenectomy of Case-10



Photograph 03: Per operative picture of spleen (Case-3), (Case-15)

DISCUSSION

β thalassemia is the most common inherited haemolytic anaemia presenting with chronic anaemia and its consequences affecting both male and female. In this study among the 20 patients 12 were male and 8 were female with the ratio 1.5:1 ($p > 0.05$). Definite male preponderance has been noted by various other authors. Porecha et al., (2009) [7] reported male-to-female ratio approximately 7:3, Al-Salem et al., (2002) [20] mentioned male to female ratio 10:1, Akhtar et al., (2016) [8] reported male to female ratio about 6:1.

In this study, Age ranges from 5-12 years with the mean of 8.18 ± 2.59 years which is consistent with other study done by Easa, (2009) [21] the mean age of patients at splenectomy was 8.75 ± 4.32 years for β thalassemia major patients. Porecha et al., (2009) [9], Bhosale et al., (2015) [22] and Akhtar et al., (2016) [8] also showed mean age at splenectomy was 9 years. Ammar et al., (2014) [9] and Al-Salem et al., (2002) [20] reported 6.68 ± 2.54 years and 8 years respectively. All the patient was transfusion dependent β thalassemia among them 16 (80%) were severe HbE/ β thalassemia and rest 4(20%) were β thalassemia major which is consistent with study done by Mannan et al., (2013) [2] who reported most of the β thalassemia patient in our country is HbE/ β thalassemia.

Among the 20 cases major indication of splenectomy was increased requirement of blood transfusion 14 (70%), huge splenomegaly causing mechanical discomfort 5(25%), and hypersplenism 1(5%). Porecha et al., (2009) [9] reported the major indication for splenectomy was higher blood transfusion requirement and Akhtar et al., (2016) [8] reported major indication of splenectomy were hypersplenism.

Various study showed that removal of the spleen improves the hemoglobin concentration and substantially reduces the transfusion needs. Akhtar et al., (2016) [8] reported blood transfusion requirements per year were decreased after splenectomy. Pecorari et al., (2008) [23] reported splenectomy reduces the transfusion requirement to half of the presplenectomy stage. Bhosale, et al., (2015) [22] found at a mean follow-up of 3 years, all children continue to reap the benefits of splenectomy, their transfusion requirement remains low than the preoperative requirement, Hb levels were maintained at a higher range >8 gm%. Aessopos et al., (2004) [24] reported in their study mean 6-monthly hemoglobin level of all patients was significantly increased postoperatively from 8.1 ± 0.6 to 9.2 ± 0.4 g/dl ($p < 0.001$) and 6-monthly transfusion requirements were significantly reduced from 28 ± 5 to 22 ± 4 units ($p < 0.001$) in thalassemia major patients, while in thalassemia intermedia patients' transfusion needs reduced by approximately 21% and discontinued in 80% patients.

In this study hematological assessment shows the mean 6-monthly hemoglobin level of all patients was significantly increased after splenectomy from 4.19 ± 0.92 g/dl to 8.66 ± 0.73 g/dl ($p < 0.001$). Postoperatively 6-monthly transfusion requirements were significantly reduced from 14.30 ± 3.18 to 2.15 ± 1.46 units ($p < 0.001$), while blood transfusions were discontinued in 4 (20%) patients. So, this study rationalized the other international studies. The mean preoperative serum ferritin concentration was 1346.25 ± 616.40 ng/ml and postoperatively 1722.60 ± 858.96 ng/ml which was not statistically significant ($p > 0.05$). This result is similar with the study by Aessopos et al., (2004) [24]. As anaemia was significantly improved after splenectomy in all patients in this study and blood transfusion as well as transfusional iron intake was reduced it was expected that serum ferritin level will decrease but not decreased, this may be due to spleen is also a storage site of iron and slow downtrend of serum ferritin level. Akhtar et al., (2016) [8] reported average ferritin level was reduced after splenectomy and cost of iron chelation also reduced. Another study by Easa, (2009) [21] reported the higher level of serum ferritin in splenectomized patients than non splenectomized patients despite the decrease of frequency of blood transfusion. In this study no patient was on iron chelation therapy before splenectomy except one who present with heart failure and serum ferritin level was more than 3000 ng/ml, intravenous iron chelation was given in that patient for management of heart failure and after splenectomy 5 patients were started oral iron chelator as their serum ferritin level was more than 2500 ng/ml but no features of heart failure. Although the role of splenectomy on iron balance is controversial, an aggravating effect of splenectomy on hemosiderosis has been suggested by some authors. Ammar et al., (2014) [9] in his study stated splenectomy improves anemia, but does not reduce iron burden. Pootrakul et al., (1981) [25] reported significantly higher serum ferritin levels in splenectomized patients with HbE/ β thalassemia than in the non splenectomized ones. Thrombocytosis is frequently encountered after splenectomy. In this study preoperatively complete blood count was done in each patient where platelet count among 20 cases was in range of 1,20,000 - 1,50,000/cu mm. After splenectomy on first postoperative period platelet count was done in each patient and found in range of 2,24,000-4,52,000/cu mm, which indicate platelet count was increased after splenectomy but none of the patient had platelet count $>5,00,000$ /cu mm and no patient developed any features of thrombosis like chest pain, abdominal pain or deep vein thrombosis.

In this study preoperative left ventricular diameters and mass were significantly higher in all patients compared to controls. All 20 patients were in a high output state, with mean cardiac output being 5.85 ± 1.72 L/min in patients versus 3.6 ± 1.03 L/min in controls ($p < 0.001$).

After splenectomy cardiac output was reduced from 5.85 ± 1.72 L/min to 4.99 ± 1.64 L/min) which is statistically significant ($p < 0.05$). Other parameters of left ventricular diameters and mass were not significantly different after splenectomy ($p > 0.05$). As cardiac output is increased in β thalassemia due to compensatory reaction to chronic anaemia, by improving anaemia after splenectomy cardiac output become reduced but changes in other parameters were not significantly improved, may be due to short period of follow up. This is similar with the study by Aessopos et al., (2004) [24].

Mean values of EF (%), E/A ratio, PASP (mm of Hg) were within normal range before and after splenectomy. But altered E/A ratio was encountered in 4 patient (1 before splenectomy, 3 after splenectomy), mild decreased EF (54%) found in 1 patient before splenectomy which was improved after splenectomy (it become 60%), increased PASP (57mm of Hg) was encountered in 1 patient before splenectomy, and which was not significantly altered after splenectomy. Aessopos et al., (2004) [24] encountered pulmonary hypertension in 7 of 32 patients (21.9%). Pal et al., (2016) [26] reported no systolic dysfunction, EF in all patient $> 50\%$ in their study which is consistent with this study. Bhosale et al., (2015) [22] done two-dimensional echo on all of their cases before splenectomy and found many of them had EF between 50% to 60% and after splenectomy on mean follow-up of 3 years 2-D echo has shown stabilization of cardiac function in few of their children.

Cardiac complication is the leading cause of mortality and morbidity in thalassemia and heart failure is the main cause of death in this patient. In this study among the 20 cases total 3 (15%) patient clinically developed heart failure before splenectomy and 17(75%) patients have no features of HF. Out of 3 heart failure patients 1(5%) have features of restrictive cardiomyopathy in echocardiogram and 2(10%) have normal findings except high cardiac output. Patients with heart failure were managed properly as per guidelines and after correction of heart failure splenectomy was done. After splenectomy during 6 months follow up period no patient developed any features of heart failure.

In β thalassemia both dilated and restrictive cardiomyopathy can occur but restrictive pattern is more common due to deposition of iron. In this study among the 20 patient's restrictive cardiomyopathy was found in 4 (20%) (1 before and 3 after splenectomy) dilated cardiomyopathy in 1(5%) before splenectomy. Among this 5 patients, 1(20%) restrictive cardiomyopathy patient developed symptomatic heart failure before splenectomy, whereas 4(80%) remain asymptomatic through the study period. It was observed that all the restrictive cardiomyopathy patients have high serum ferritin level > 2500 ng/ml. This study reveals post-splenectomy haemoglobin level is increased and maintained, simultaneously reduce transfusional requirement but serum ferritin level does not altered. Cardiac output decreased from high state after splenectomy but all other parameters were not improved but no further deterioration occurred within follow up period.

LIMITATIONS OF THE STUDY

Sample size is small and purposive.

It is a single centered study.

Follow up period is short for evaluation of cardiac changes.

CONCLUSION

Splenectomy stabilizes the hemoglobin concentration at higher levels and reduces transfusion needs, reduces high cardiac output and prevents high output failure. Though other cardiac parameters remain unchanged within the first 6 months after splenectomy, it can be assumed that removal of the spleen may contribute to the prevention of further cardiac damage. Splenectomy does not affect serum ferritin level significantly within first 6 months though it reduces transfusional iron intake.

Echocardiography is widely available, relatively inexpensive, simple, non-invasive way of assessing early cardiac alterations in β thalassemia patients and marked improvement in survival of these patients can be achieved by monitoring of cardiac function with this simple test. Regular assessment of cardiac function may help to reduce the morbidity and mortality to a great extent.

RECOMMENDATIONS

Splenectomy should not be delayed when indicated. Yet, even after decades of experience, long-term outcomes of splenectomy on cardiac status have not been established. So, it is recommended to study on a large sample over long period of time in this regard. Echocardiography is recommended for an early detection and long-term monitoring of cardiac dysfunction in β thalassemia patients before and after splenectomy on regular basis and proper iron chelation therapy according to serum ferritin level is also recommended to improve the life expectancy of these patients.

REFERENCES

1. Khan, W.A., Banu, B., Amin, S.K., et al., 2005, 'Prevalence of β -Thalassaemia Trait & Hb E trait in Bangladesh School Children and Health Burden of Thalassaemia in our population'. Dhaka Shishu (Child) Hospital Journal; 21 (11):1-7.
2. Mannan, A., Kawser, J., et al., 2013, 'A Demographic Approach for Understanding the Prevalence of β Thalassemia Patterns and Other Hemoglobinopathies: Selective Study in Chittagong City Perspective'. Asian Journal of Bio Sci; 6(2): 124-130.
3. Viprakasit, V., Origa, R., et al., 2014, 'Genetic Basis, Pathophysiology and Diagnosis; Guidelines for the Management of TDT [Internet]. 3rd edition. Nicosia (CY): TIF.
4. Aster, J.C., 2006, 'Red blood cell and Bleeding disorder' In Kumar, V., Abbas, A.K., 'Robbins and Cortan's pathologic Basis of Disease.' 7th ed. Saunders, an imprint of Elsevier Inc.; Philadelphia.
5. Manglani, M.V., Pandrowala, A., Sharma, R., et al., 2016, 'Thalassemia syndromes' in Lokeshwar, M.R., 'Textbook of Pediatric Hematology and Hemato-Oncology', 1st Edi: Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, Philadelphia.
6. Galanello, R., Origa, R., et al., 2010, 'Beta-thalassemia'. Orphanet J Rare Dis; 5(11):1-15
7. Porecha, M., Udani, D., Mehta, V., et al., 2009, 'Splenectomy in Management of Thalassemia Major-A Boon For The Little Angel'. The Internate Journal of Surgery; 24(1):1-11.
8. Akhtar, I.K., Ashraf, M., Khalid, I.U., Hussain, M., et al., 2016, 'Surgical outcome of splenectomy in Thalassemia major in children'. Pak J Med Sci.; 32(2):305-308.
9. Ammar, S.A., Elsayhb, K.I., Zahran, A. M., et al., 2014, 'Splenectomy for patients with β - thalassemia major: long-term outcomes'. The Egyptian Journal of Surgery. ; 33:232-236
10. Taher, A., Tyan P. et al., 2014, 'THE SPLEEN'; Guidelines for the Management of TDT [Internet]. 3rd edition. Nicosia (CY): TIF
11. Azarkeivan, A., Mehrvar, A., Faranoush, M., et al., 2009, 'Cardiac Involvement in Patients with Transfusion Dependent β Thalassemia'. Research Journal of Biological Sciences; Vol:4 (2):195-199.
12. Prabhu, R., Prabhu, V., Prabhu, R.S., et al., 2009, 'Iron Overload in Beta Thalassemia- A Review'. J Biosci Tech.; 1(1): 20-31.
13. Jha, R., Jha, S., et al., 2014, 'Beta thalassemia - a review'. Journal of Pathology of Nepal; Vol:4: 663-671.
14. Maggio, A., Vitrano, A., Calvaruso, G., 2013, 'Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death'; Blood Cells, Molecules and Diseases; 50 :241-246
15. Hyder, S.N., Kazmi, U., Malik, A., et al., 2013, 'An Ecocardiographic Evaluation of Left Ventricular Function in Patients with Thalassemia Major'. J Pak Med Stud; 3(1): 10-15.
16. Eshaqhoseni, K., Miri, R., Arsang, S.H., 2014. 'Cardiac Disorders in Children with B-Thalassemia Major', Bulletin of Environment, Pharmacology and Life Sciences; 3(9): 172-175
17. Sayed, S.Z., Aly, B.A., Omar S.M., et al., 2013, 'The early cardiac involvement in patients with β -thalassemia major', The Egyptian Heart Journal; 65: 243-249
18. Walker, M., Wood, J., Taher, A., et al., 2014, 'Cardiac Complications in Thalassaemia Major', Guidelines for the Management of TDT [Internet]. 3rd edi. Nicosia (CY): TIF
19. Khalilian, M.R., Moghaddar, R., Emami-Moghadam, A. et al., 2016, 'Evaluation of the Correlation between Echocardiographic Findings and Serum Ferritin in Thalassemia Major Patients'. Global Journal of Health Science; Vol. 8(12);190-196

20. Al-Salem, A.H., Nasserulla, Z., et al., 2002, 'Splenectomy for children with thalassemia'. *Int J Surg.*;87(4):269-273.
21. Easa, Z.O., et al., 2009, 'Complications of High Serum Ferritin Level after Splenectomy in β Thalassemic Patients'. *KufaMed. Journal*; vol.12(1): 243-250.
22. Bhosale, M., Chandanwale, A., Kinikar, A., et al.,2015, 'Impact of splenectomy on quality of life of children with β -thalassemia'. *International Journal of Medicine and Public Health*;Vol:5(4):322-327.
23. Pecorari, L., Savelli, A., Guna, C.D., et al.,2008, 'The Role of Splenectomy in Thalassemia Major'. An Update. *Acta Paediatrica Mediterranea.*;24:57-60.
24. Aessopos, A., Farmakis, D., Tsironi, M. et al.,2004, 'Hemodynamic assessment of splenomegaly in β -thalassemia patients undergoing splenectomy'. *Ann Hematol*; vol: 83: 775–778.
25. Pootrakul, P., Vongsmasa, V., La-Onghanich, P., & Wasi, P. (1981). Serum ferritin levels in thalassemias and the effect of splenectomy. *Acta haematologica*, 66(4), 244-250.
26. Pal, A.C., Mukherjee, R., Sinha, P.,et al.,2016, 'A Study on Thalassemic Children to Assess Cardiovascular Changes, In a Rural Medical College Hospital; West Bengal; India'. *IOSR Journal of Dental and Medical Sciences*;15(4):43-47.

Appendix-I

Consent form

(Verbally translated into Bengali)

I, hereby give my well-informed consent for participation of my child in the study conducted by Dr. Naznin Aktar Sheuli of department of Paediatric Surgery, Mymensingh Medical College & Hospital, Mymensingh. I have fully understand that participation in this study will bring fruitful medical information for my child and many in the future.

I am convinced that participation in this study my child will not be exposed to any physical, psychological, social or legal risk. The privacy and confidentiality of my child and that of myself will be safeguarded and our anonymity will be protected. I would not claim any monetary benefit for this.

Signature / Thumb impression

(Parent / legal guardian)

Date:

Appendix-II

DATA COLLECTION SHEET

1. Case serial no:

2. Hospital reg. no.:

3. Ward/Bed :

4. Date of data collection :

5. Particulars of the patients:

Name:

Informant:

Age:
Sex:
Father's name :
Mother's name:

Address:
Date of admission :
Date of discharge :
Contact number :

6. Presenting complaints:

7. History of present illness :

8. Past history :

9. Treatment history :

- ✓ Duration of blood transfusion:
- ✓ Frequency of blood transfusion :
- ✓ Quality of blood transfused: Whole fresh blood/Packed red cell
- ✓ History of taking iron chelation therapy :
- ✓ Any other treatment history :

10. Family history:

Consanguinity:
Father:
Mother:
Other sibling:

11. Immunization history:

12. Socio-economic history:

13. General Physical Examination:

Appearance:	Respiratory rate:
Body built:	Temperature:
Nutrition :	Blood pressure:
Anaemia:	JVP:
Jaundice:	Weight :
Cyanosis:	Height :
Edema:	Thyroid gland :
Dehydration:	Accessible lymph nodes :
Pulse:	Skin condition :

14. Systemic examination:

A. Abdomen examination:

a) Inspection

Size & shape:

Distension :

Umbilicus :

Visible peristalsis :

Hernial orifices :

b) Palpation

Temperature :

Tenderness :

Deep palpation -

Liver:

Spleen : Size:

Kidney:

Urinary bladder :

c) Percussion

Percussion note:

d) Auscultation

Bowel sound :

Any bruit :

B. Cardio vascular System examination:

Precordium:

(a) Inspection:

Shape of the chest:

Any visible impulse/apex beat:

(b) Palpation:

Apex beat:

Thrill:

(c) Auscultation:

Heart sound:

Added sound:

15. Other Systemic Examination:

Lungs: Bilateral basal crepitation present/absent:

16. Type of β thalassemia:

Hb electrophoresis report:

17. Indication of Splenectomy :

Blood transfusion requirement/kg/year:

H/O mechanical discomfort:

Review of past medical records suggestive of Hypersplenism (if any):

Peripheral blood film (if any):

Bone marrow examination report (if any):

18. Investigations:

A. Laboratory tests:

Complete blood count :

PBF:

Serum bilirubin:

HBs Ag:

S.SGPT:

S.ferritin :

PT :

Serum creatinine:

B. Imaging study:

Chest X-ray P/A view:

Echocardiogram :

19. Pre-operative preparation:

- ✓ Pre-operative blood transfusion to maintain Hb level >8gm/dl
- ✓ Management of Heart failure or any other complication before splenectomy
- ✓ Nothing per oral 6 hours before the operation

20. Operation note:

- ✓ Date of operation:
- ✓ Anesthesia:
- ✓ Per-operative findings:
 - Spleen condition:
 - Gall stone present/absent:
 - Any accessory spleen:

21. Postoperative management :

- ✓ Nothing per oral for 24-36 hours
- ✓ Nasogastric suction
- ✓ Antibiotics
- ✓ Analgesic
- ✓ **At 1st post-operative day :**

Hb% -

Total platelet count-

22. Any post-operative complication:

23. Post-operative follow-up : Follow-up first visit 2 weeks after splenectomy and then 1-month interval to the out-patient department of paediatric surgery over 6months postoperatively.

Visit	Hb level (gm/dl)	Blood transfusion require(units) or not	Others
1 st visit 2wks after splenectomy			PBF (if needed):
2 nd visit 1 month after splenectomy			
3 rd visit 2 months after splenectomy			
4 th visit 3 months after splenectomy			
5 th visit 4 month after splenectomy			
6 th visit 5 month after splenectomy			
7 th visit 6 month after splenectomy			Echocardiogram : S. ferritin(ng/ml):

--	--	--	--

24. Calculation of Mean 6-monthly pretransfusion hemoglobin 6 months period preceding splenectomy and 6 months period following splenectomy

SL No.	Pretransfusion hemoglobin level (gm/dl) in 6 months period preceding splenectomy (from past medical records)	Pretransfusion hemoglobin level (gm/dl) in 6 months period following splenectomy (from follow up schedule)
Average		

25. 6-months transfusion requirements before and after splenectomy:

Variable	6-months period preceding splenectomy (from past medical records)	6-months period following splenectomy (from follow up schedule)
Transfusion requirement(units)		

26. S.ferritin level (ng/ml) before and 6 months after splenectomy:

Variable	Before splenectomy	6 months after splenectomy.
S.ferritin level (ng/ml)		

27. Echocardiogram findings: Before splenectomy & 6 months after splenectomy:

A. Left ventricular dimensions and mass before and 6 months after splenectomy:

Variables	Before	After
IVSTd (mm)		
LVIDd (mm)		
LVPWTd (mm)		

IVSTs (mm)		
LVIDs (mm)		
LVPWTs (mm)		
LV MASSd (g)		

B. Left ventricular stroke volume and calculation of Cardiac output by $SV \times HR$ before and 6months after splenectomy:

Variables	Before splenectomy	6 months after splenectomy
SV (ml)		
HR (beats/min)		
CO=$SV \times HR$ (ml/min)		
CO (L/min)		

C. Parameters for LV systolic function (EF), diastolic function (E/A ratio) and pulmonary hypertension (PASP) before and 6months after splenectomy:

Variables	Before splenectomy	6 months after splenectomy
EF (%)		
E/A ratio		
PASP(mm of Hg)		